Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a parasite drug beat warts? new trial tests ivermectin

NCT ID NCT07396714

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial will test whether a cream containing ivermectin (a drug used for parasites) can treat common skin warts. It will compare ivermectin alone, ivermectin combined with microneedling (tiny needles to help the cream absorb), and a standard salicylic acid treatment. The study plans to enroll 88 people aged 11 to 80 with non-genital warts and will check results every two weeks for up to 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
topical ivermectin 1%
What this could lead to
If it works, this could offer a new topical treatment option for common skin warts.
What could go wrong
This is a very early, small trial (88 people) with no results yet. The treatment may not work better than existing options, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

11 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with cutaneous non genital warts aged 11:80 y. * No concurrent systemic or topical treatment of warts Exclusion Criteria: * Genital warts. * Pregnancy and lactation. * History of any bleeding, clotting disorder or using anticoagulants * Chronic systemic diseases such as chronic renal failure, hepaticinsufficiency, and cardiovascular disorders. * patients who received any treatment for warts in the last month before the study. * Patients with history of neuropathy or peripheral ischemia. * Patients with signs of inflammation or infection. * Patients with history of a serious systemic or anaphylactic reaction or allergy to ivermectin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Warts are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common wart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Warts

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.